公开(公告)号：US20180148432A1

公开(公告)日：2018-05-31

申请号：US15820679

申请日：2017-11-22

Applicant: Pfizer Inc.

Inventor： Natasha Mariam Kablaoui ,  Michael Eric Green ,  Justin Ian Montgomery ,  Michael Aaron Brodney ,  Patrick Robert Verhoest ,  Gregory Wayne Kauffman ,  Danica Antonia Rankic ,  Scot Richard Mente ,  Bruce Nelsen Rogers ,  Kapildev Kashmirilal Arora ,  Matthew Francis Dunn

IPC: C07D403/04 ,  C07D417/04 ,  A61P25/00 ,  C07D231/20 ,  C07D413/04

CPC classification number: C07D403/04 ,  A61P25/00 ,  C07B2200/13 ,  C07D231/20 ,  C07D413/04 ,  C07D417/04

Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.

公开(公告)号：US20150274721A1

公开(公告)日：2015-10-01

申请号：US14670746

申请日：2015-03-27

Applicant: Pfizer Inc.

Inventor： Martin Youngjin Pettersson ,  Christopher William am Ende ,  John Michael Humphrey ,  Douglas Scott Johnson ,  Gregory Wayne Kauffman ,  Danica Antonia Rankic ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中化合物具有式I的结构，其中X，R1，R2a，R2b，R4a，R4b，R5a，R5b，R6，R7，y和z如本说明书中所定义 。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。

公开(公告)号：US20240366598A1

公开(公告)日：2024-11-07

申请号：US18634154

申请日：2024-04-12

Applicant: Pfizer Inc.

Inventor： Kevin James Filipski ,  Matthew Forrest Sammons ,  Samuel Michael Levi ,  Yang Wang ,  Advaita Panchagnula ,  Yanfei Guan ,  Matthew Richard Reese ,  Luis Angel Martinez Alsina ,  Steven Victor O'Neil ,  Lei Zhang ,  Qifang Li ,  Ethan Lawrence Fisher ,  Danica Antonia Rankic

IPC: A61K31/506 ,  A61K31/403 ,  A61K31/4439 ,  A61K31/444 ,  A61P3/04 ,  C07D207/16 ,  C07D209/52 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12

Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, L1, T1, T2, T3, T4, t1, and t2 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.

公开(公告)号：US20170166566A1

公开(公告)日：2017-06-15

申请号：US15441882

申请日：2017-02-24

Applicant: Pfizer Inc.

Inventor： Martin Youngjin Pettersson ,  Christopher William am Ende ,  John Michael Humphrey ,  Douglas Scott Johnson ,  Gregory Wayne Kauffman ,  Danica Antonia Rankic ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b,R5a, R5b, R6, R7, y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US20240150334A1

公开(公告)日：2024-05-09

申请号：US18482129

申请日：2023-10-06

Applicant: Pfizer Inc.

Inventor： Jan Antoinette Cusi Romero Adams ,  Bruce Michael Bechle ,  Jason Kenneth Dutra ,  Michelle Renee Garnsey ,  Xinjun Hou ,  Jisun Lee ,  Deane Milford Nason, II ,  Steven Victor O'Neil ,  Danica Antonia Rankic ,  Yang Wang ,  Ann Sorrentino Wright ,  Lei Zhang ,  Liying Zhang ,  David James Edmonds

IPC: C07D413/04 ,  C07D231/56 ,  C07D263/56 ,  C07D401/04 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D498/04 ,  C07D513/04

CPC classification number: C07D413/04 ,  C07D231/56 ,  C07D263/56 ,  C07D401/04 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D498/04 ,  C07D513/04

Abstract: Described herein are compounds of Formula I,




wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD and NASH.

公开(公告)号：US10316021B2

公开(公告)日：2019-06-11

申请号：US15820679

申请日：2017-11-22

Applicant: Pfizer Inc.

Inventor： Natasha Mariam Kablaoui ,  Michael Eric Green ,  Justin Ian Montgomery ,  Michael Aaron Brodney ,  Patrick Robert Verhoest ,  Gregory Wayne Kauffman ,  Danica Antonia Rankic ,  Scot Richard Mente ,  Bruce Nelsen Rogers ,  Kapildev Kashmirilal Arora ,  Matthew Francis Dunn

IPC: C07D403/04 ,  C07D231/20 ,  C07D413/04 ,  C07D417/04 ,  A61P25/00

Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.